Phase II study of sorafenib in patients with advanced hepatocellular carcinoma Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • Benzenesulfonates
  • Carcinoma, Hepatocellular
  • Liver Neoplasms
  • Protein Kinase Inhibitors
  • Pyridines

abstract

  • Although single-agent sorafenib has modest efficacy in HCC, the manageable toxicity and mechanisms of action support a role for combination regimens with other anticancer agents.

publication date

  • September 10, 2006

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1200/JCO.2005.01.3441

PubMed ID

  • 16908937

Additional Document Info

start page

  • 4293

end page

  • 300

volume

  • 24

number

  • 26